Tricida

Leadership team

Dr. Gerrit Klaerner Ph.D. (Founder, Pres, CEO & Exec. Director)

Mr. Geoffrey M. Parker (COO, CFO & Exec. VP)

Mr. Robert L. McKague J.D. (Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer)

Products/ Services

Health Care, Medical, Pharmaceutical

Number of Employees

50 - 100

Headquarters

Menlo Park, California, United States

Established

2013

Company Registration

SEC CIK number: 0001595585

Traded as

TCDA

Social Media

URL

https://www.tricida.com

Overview

Location

Recognition and Award

References

Summary

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

History

Tricida was founded in 2014 by Fred Rahmanian and is headquartered in South San Francisco, California. The company's focus is to develop medicines to reduce the metabolic acidosis burden observed in patients with chronic kidney disease.

Mission

Our mission is to develop and commercialize novel, orally administered therapies to reduce the metabolic acidosis burden associated with chronic kidney disease.

Vision

Our vision is to provide better treatments and quality of life for kidney disease patients.

Key Team

Dr. Dawn Parsell Ph.D. (Exec. VP of Clinical Devel.)

Ms. Annie Yoshiyama (VP of Fin. & Chief Accounting Officer)

Jackie Cossmon (VP of Investor Relations & Communications)

Mr. Edward J. Hejlek Esq., J.D. (Exec. VP of Intellectual Property)

Recognition and Awards

Tricida has earned numerous medical awards like Innovation Award For Best Technology and Most Innovative Product of the Year Award in 2019. In 2020, it was also awarded the Outstanding Achievement in Drug Discovery Award.